These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17632533)

  • 1. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.
    Tilson HH; Madre LK; Califf RM
    Clin Pharmacol Ther; 2007 Aug; 82(2):118-21. PubMed ID: 17632533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety.
    Lo Re V; Strom BL
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):818-25. PubMed ID: 17436357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the Institute of Medicine review the FDA?
    Carroll BJ
    Nat Med; 2005 Apr; 11(4):369. PubMed ID: 15812509
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to "Can the Institute of Medicine review the FDA?".
    Fineberg HV
    Nat Med; 2005 Jun; 11(6):589. PubMed ID: 15937463
    [No Abstract]   [Full Text] [Related]  

  • 7. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 8. Blueprint for a stronger Food and Drug Administration.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
    [No Abstract]   [Full Text] [Related]  

  • 9. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of drug safety.
    Breckenridge A
    Clin Pharmacol Ther; 2007 Feb; 81(2):161-3. PubMed ID: 17259942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IOM: congress must reform FDA to improve drug safety.
    Young D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2032, 2034. PubMed ID: 17057032
    [No Abstract]   [Full Text] [Related]  

  • 12. The need for a national infrastructure to improve the rational use of therapeutics.
    Califf RM
    Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):319-27. PubMed ID: 12138600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA reform: is it enough? After a critical IOM report, agency moves to work harder on drug safety, but Congress presses ahead with its own changes.
    Robeznieks A
    Mod Healthc; 2007 Feb; 37(6):6-7, 1. PubMed ID: 17312931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    Jones JK
    Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 16. Review and critique of the Institute of Medicine report "the future of drug safety".
    Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):158-61. PubMed ID: 17259941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 18. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 19. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 20. Advancing the science of pharmacovigilance.
    Honig PK
    Clin Pharmacol Ther; 2013 Jun; 93(6):474-5. PubMed ID: 23689213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.